Compare SCLX & KULR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCLX | KULR |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electrical Products |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.3M | 163.0M |
| IPO Year | N/A | N/A |
| Metric | SCLX | KULR |
|---|---|---|
| Price | $14.09 | $3.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 71.9K | ★ 1.9M |
| Earning Date | 11-14-2025 | 11-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $40,360,000.00 | $16,677,036.00 |
| Revenue This Year | N/A | $64.40 |
| Revenue Next Year | $749.70 | $105.13 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 71.92 |
| 52 Week Low | $3.60 | $2.15 |
| 52 Week High | $34.27 | $43.92 |
| Indicator | SCLX | KULR |
|---|---|---|
| Relative Strength Index (RSI) | 36.11 | 50.21 |
| Support Level | $12.87 | $2.96 |
| Resistance Level | $20.62 | $3.66 |
| Average True Range (ATR) | 1.04 | 0.35 |
| MACD | -0.37 | 0.01 |
| Stochastic Oscillator | 18.54 | 33.54 |
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems, artificial intelligence and Cloud computing, energy storage, 5G communication technologies, and other consumer and industrial devices.